Marijuana users found to have 16% lower fasting insulin levels than non-users
Marijuana use has been associated with lower fasting insulin levels
<p> </p> <div> People who smoke marijuana have been found to have 16 per cent lower fasting insulin levels than non-users, according to research published in The American Journal of Medicine.</div> <div> </div> <div> In light of the findings, professor of medicine at the University of Arizona College of Medicine, Tucson, Joseph Albert, called for more basic and clinical research into the short and long-term effects of marijuana in a variety of clinical settings, including cancer and diabetes. </div> <div> </div> <div> Data from 4,657 patients who completed a drug questionnaire was used to inform the research. Some 579 were current marijuana users, while 1,975 had used it in the past. </div> <div> </div> <div> Those who reported using marijuana in the past month had lower levels of fasting insulin and HOMA-IR. The link was weaker in candidates that reported using marijuana at least once, but not in the past 30 days. </div> <div> </div> <div> Professor Albert commented: "These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions."</div> <div> </div> <div> Previous studies have shown that while marijuana users tend to take in more calories, they often have lower body mass indexes and smaller waist circumferences. </div>
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...